Navigation Links
Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
Date:1/8/2009

SAN DIEGO, Jan. 8 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX) today announced that the first of four Phase 3 trials of its lead investigational product Contrave(R) (naltrexone sustained release (SR)/bupropion SR) met its co-primary and key secondary endpoints, showing a significant reduction in body weight, improvements in markers of cardiovascular risk and reductions in selected food craving measures.

In this trial, which included an intensive diet and exercise behavior modification regimen, obese patients treated with Contrave, based on intent-to-treat (ITT) and completer analyses, lost an average of 20.3 pounds to 25.0 pounds, or 9.3% to 11.5% of their baseline body weight, versus 11.0 pounds to 16.0 pounds, or 5.1% to 7.3% of baseline body weight, for patients treated with placebo. In addition, in the categorical weight reduction analysis, the percentage of patients who lost greater than or equal to 10% of their body weight was 20.2% in the placebo group compared to 41.5% in the Contrave group. We believe these results satisfy the categorical FDA efficacy benchmark for clinically significant weight loss. All of these findings were highly statistically significant (p<0.001).

Contrave was generally well tolerated by patients. The overall safety profile of Contrave was consistent with its individual components, naltrexone and bupropion, two drugs that have been used separately in patients for over 20 years. Treatment with Contrave was not associated with increases in symptoms of depression, suicidality or worsening of mean blood pressure.

"The results of this trial indicate that additional, clinically significant weight loss can be achieved when Contrave is added to a rigorous program of diet and exercise," said Eduardo Dunayevich, Chief Medical Officer, Orexige
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
2. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
3. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
4. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
5. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
6. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
7. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
8. InteKrin Therapeutics to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13
9. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
10. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
11. Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 2014 a2z Inc. announces that AACC ... AACC Pathfinder, in its 2014 Annual Meeting & ... is planned for July 29-31, 2014 in Chicago, IL ... to connect with global leaders in clinical chemistry, molecular ... areas of breaking science in laboratory medicine. , ChirpE ...
(Date:7/22/2014)... Web) July 21, 2014 (PRWEB) July 23, 2014 ... Biomaterials, at Rutgers University. , The goal ... ideas across the full spectrum of scientists working ... research and development topics that represent the most ... been programmed to:,     Provide faculty ...
(Date:7/22/2014)... National Institute of Standards and Technology (NIST) and ... new design for an atomic clock that is ... microcomb. , The microcomb clock, featured on the ... journal Optica ,* is the first demonstration ... accurate conversion of optical frequencies to lower microwave ...
(Date:7/22/2014)... 22, 2014   BioTE Medical , a ... bio-identical hormone pellets, today announced the addition of ... company.   Dr. Rouzier is joining the BioTE Medical ... Dr. Rouzier was residency trained in Family ... a board certified emergency physician still practicing at ...
Breaking Biology Technology:AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 3The 2014 NJ Symposium on Biomaterials Science Earns Society for Biomaterials Endorsement 2'Comb on a chip' powers new NIST/Caltech atomic clock design 2Dr. Neal Rouzier Joins BioTE Medical 2Dr. Neal Rouzier Joins BioTE Medical 3
... at Ohio State University have invented a lens that enables ... once to create a 3D image. Other 3D microscopes ... the new lens is the first single, stationary lens to ... professor of integrated systems engineering at Ohio State, and postdoctoral ...
... 2011 Coinstar, Inc. (Nasdaq: CSTR ... a consumer-driven healthcare technology company that develops and ... award-winning EyeSite® product and the next-generation SoloHealth Station™. ... "As a leader in automated retail, Coinstar is ...
... Tomo will auction a patent portfolio disclosing an ... ICAP Ocean Tomo Spring 2011 Live IP Auction in ... improvements to existing nebulizer devices. (Logo:   ... the use of nebulizers for pulmonary drug delivery to ...
Cached Biology Technology:Seeing in stereo: Engineers invent lens for 3-D microscope 2Coinstar to Invest in SoloHealth 2Coinstar to Invest in SoloHealth 3ICAP Ocean Tomo Announces the Auction of an Improved Compact, Portable Nebulizer Developed and Patented by Tidal Air 2ICAP Ocean Tomo Announces the Auction of an Improved Compact, Portable Nebulizer Developed and Patented by Tidal Air 3ICAP Ocean Tomo Announces the Auction of an Improved Compact, Portable Nebulizer Developed and Patented by Tidal Air 4
(Date:7/22/2014)... squirrels have adapted to New York City,s human behaviour, ... better, than their fellow squirrels in the woods. , ... Environment & Agriculture, led the study that proved eastern ... urban environments and prevent unnecessary responses when humans acted ... footpath. , "As we rapidly increase the spread ...
(Date:7/22/2014)... The darker side of meerkats which sees them prevent ... explained in a new study. , Research into the desert ... pair and many adult helpers shows that the alpha ... breed. , The study shows how this way of life, ... can prove effective despite its sinister side. , Dominant ...
(Date:7/21/2014)... of Middle East Respiratory Syndrome coronavirus (MERS-CoV) in the ... the virus. The work, published this week in ... Society for Microbiology, indicates that further studies are needed ... the air. , MERS, a serious viral respiratory illness ... people as of June 11, according to the World ...
Breaking Biology News(10 mins):New York squirrels are nuts about city life 2Middle East Respiratory Syndrome coronavirus detected in the air of a Saudi Arabian camel barn 2
... demonstrated how nerve stimulation paired with specific experiences, such as ... lead to new treatments for stroke, tinnitus, autism and other ... at Dallas neuroscientists showed that they could alter the speed ... stimulation of the vagus nerve with fast or slow sounds. ...
... This release is available in German . ... are found to be spread widely throughout the oceans ... Antarctica. They live freely in the water, in sediments and ... for their pink colour. Marine bacteria distinguish themselves through an ...
... Baby Boomers to eat its spinach. Today, role models such ... eating habits, a recent Cornell University study finds. , "Fast ... their parents. Simply instructing a parent to order healthier food ... easy for a parent," said Brian Wansink, Cornell professor of ...
Cached Biology News:Reorganizing brain could lead to new stroke, tinnitus treatments 2Reorganizing brain could lead to new stroke, tinnitus treatments 3Think pink! Success of pink bacteria in oceans of the world 2Think pink! Success of pink bacteria in oceans of the world 3
BD BioCoat Gelatin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of gelatin....
The F40 piston assembly is supplied as two assemblies to service one F40 pump of a BioLogic DuoFlow workstation....
... 5-OxoETE-d7 is used as an internal ... stable isotope dilution mass spectrometry. 5-OxoETE is ... oxidation of 5-HETE in human neutrophils. It ... an EC50 of 2 nM. 5-OxoETE selectively ...
...
Biology Products: